Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.
about
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activityThe HIV glycan shield as a target for broadly neutralizing antibodiesMass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycansComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesGlycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodiesA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesMALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans.Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicityVariable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.The sweet and sour of serological glycoprotein tumor biomarker quantification.Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cellsEnzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry.Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked HydrogelHIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120Analytical performance of immobilized pronase for glycopeptide footprinting and implications for surpassing reductionist glycoproteomicsN-Terminal clustering of the O-glycosylation sites in the Mycobacterium tuberculosis lipoprotein SodC.Structural principles controlling HIV envelope glycosylation.Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity.Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralizationLack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimerGlycosylation profiling to evaluate glycoprotein immunogens against HIV-1.Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy.Macrophage-derived simian immunodeficiency virus exhibits enhanced infectivity by comparison with T-cell-derived virus.Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.Quantification, 2DE analysis and identification of enriched glycosylated proteins from mouse muscles: Difficulties and alternatives.Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan
P2860
Q21076115-44526B86-2EF6-4F74-8574-147C03EF4894Q26786540-C9C1BA6E-A9DB-4AC9-A89D-38631E54418BQ27485679-77A0D53B-C962-44DB-A975-B740951C7D87Q27674878-6D255851-E39C-4D1D-A7AC-A961A88D00A9Q28263932-0615391C-0C50-4316-9311-177914CF6E12Q28299280-FAD61702-9FF4-4301-B4EC-4241D52946D7Q31095515-784523E4-3618-4D91-8423-5285CB130F14Q33323199-69943482-40BC-471A-8F6C-CC7BFA31F4C7Q33345100-3C629CA6-2661-48B5-B97A-898C5B725882Q33840789-D0907357-BDE3-4ECD-8065-3DDF18746F3FQ34175370-51493AA8-685F-48B1-9C2F-09D82281BA22Q34178201-F75B0262-F887-451F-9FBF-ADA4BA51AE9EQ34299053-E5B77531-A3B9-4D75-AFB8-97CD74CAA3F7Q34432690-E3364CF4-DF2C-4661-9CF9-FD30FB4337F3Q34580285-F6338422-C359-459F-9425-837803304397Q34658136-1E04AA32-10CD-45FC-AB35-45795A6B37ACQ34796885-8604DD61-5BE1-44D6-AC6F-3994E29FAA57Q35076987-A244C3E0-5225-401B-B696-8C5C42489BDDQ35140429-9409E39D-2502-4025-B45C-5EFD703D20C6Q36242593-4D84D0CF-97BB-4101-8AEE-6EC3D8F76FAFQ36340471-DF98B684-B6EC-4D58-A34E-602A64203D63Q36664069-C56A7307-0968-4483-882E-763C23D3347CQ36747989-2EBD9CE0-4968-4CC4-BC1D-748843FAB205Q36748055-9FA60F89-6E82-4E7A-8FA4-F3CA9DFBEF07Q37087199-3EA4F01F-6D99-476B-8B38-D6546DE624A8Q37323231-77365212-53A1-4A84-819F-2CA9ADF21AB3Q39211319-5C566F3D-BF50-4FC0-B147-74A34BB8F4D8Q39593941-26E6B288-80DF-4341-B8B6-778DD42AE3F7Q39723388-D30AD6CB-6882-4378-805D-490A9F88252DQ39725329-F7A13D20-D33D-402A-BF0E-216EFC2DC2F5Q39949085-FC228DAB-CC8A-4323-845B-A37FA32155F6Q40058876-96C01E87-76F4-4D68-A6A1-E1D3588F0803Q41341684-20D27FFD-B0AB-4511-9929-DCD3F8FF2E61Q41914053-1D79E1CC-329F-416A-9EE0-3E6C73494A48Q42265635-CFF630E6-23F6-4394-97DA-B04861080104Q50207576-9644343C-6F71-44D2-A220-1135437F3DDCQ57292375-E9D99451-5119-4487-82BB-65B4E9AEE4D4
P2860
Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Characterization of glycopepti ...... omatography mass spectrometry.
@ast
Characterization of glycopepti ...... omatography mass spectrometry.
@en
type
label
Characterization of glycopepti ...... omatography mass spectrometry.
@ast
Characterization of glycopepti ...... omatography mass spectrometry.
@en
prefLabel
Characterization of glycopepti ...... omatography mass spectrometry.
@ast
Characterization of glycopepti ...... omatography mass spectrometry.
@en
P2093
P2860
P1476
Characterization of glycopepti ...... omatography mass spectrometry.
@en
P2093
Jenny M Cutalo
Kenneth B Tomer
Leesa J Deterding
P2860
P2888
P304
P356
10.1016/J.JASMS.2004.07.008
P577
2004-11-01T00:00:00Z
P5875
P6179
1009225723